PALOMA-2 was a phase 3 study of palbociclib and letrozole as first-line therapy for postmenopausal women with ER + , human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer who had no prior treatment for advanced disease12,13. This evidence concerns the gene ERBB2 and breast cancer.